Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00229723 · ClinicalTrials.gov registry record · Phase 2
IRESSA™ (Gefitinib) With Cisplatin Plus Radiotherapy for the Treatment of Previously Untreated Unresected Late Stage III/IV Non-Metastatic Head and Neck Squamous Cell Carcinoma
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 224
- Enrollment target
NCT00229723 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 224 participants.
The verdict
NCT00229723, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 224 participants
- Enrollment target
Study Summary
The primary purpose of this study is to assess the effectiveness of ZD1839 250 mg and 500 mg when given either concomitantly or as maintenance to a standard therapy of radiotherapy (X-rays) plus chemotherapy (cisplatin) in terms of local disease control (progression-free) rate at 2 years.
Interventions
- DRUG cisplatin
- RADIATION radiotherapy
- DRUG gefitinib (Iressa)
- DRUG Gefitinib (Iressa)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 224 participants |
| Start Date | 2004-11 |
| Est. Completion | 2008-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00229723
The ClinicalTrials.gov registry entry for NCT00229723 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 224 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which cisplatin is the first listed.
NCT00229723 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00229723 about?
NCT00229723 is a clinical study titled "IRESSA™ (Gefitinib) With Cisplatin Plus Radiotherapy for the Treatment of Previously Untreated Unresected Late Stage III/IV Non-Metastatic Head and Neck Squamous Cell Carcinoma". The primary purpose of this study is to assess the effectiveness of ZD1839 250 mg and 500 mg when given either concomitantly or as maintenance to a standard therapy of radiotherapy (X-rays) plus chemotherapy (cisplatin) in terms of local disease control (progression-free) rate at 2 years.
What is the current status of trial NCT00229723?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 224 participants. The study started on 2004-11. Estimated completion is 2008-06.
What interventions are being tested in trial NCT00229723?
The interventions under investigation include: cisplatin (DRUG), radiotherapy (RADIATION), gefitinib (Iressa) (DRUG), Gefitinib (Iressa) (DRUG).
Who is sponsoring clinical trial NCT00229723?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.